-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Liver -X- _ O
fluke -X- _ O
infection -X- _ O
of -X- _ O
livestock -X- _ O
causes -X- _ O
economic -X- _ O
losses -X- _ O
of -X- _ O
over -X- _ O
US -X- _ O
$ -X- _ O
3 -X- _ O
billion -X- _ O
worldwide -X- _ O
per -X- _ O
annum. -X- _ O
The -X- _ O
disease -X- _ O
is -X- _ O
increasing -X- _ O
in -X- _ O
livestock -X- _ O
worldwide -X- _ O
and -X- _ O
is -X- _ O
a -X- _ O
re-emerging -X- _ O
human -X- _ O
disease. -X- _ O
There -X- _ O
are -X- _ O
currently -X- _ O
no -X- _ O
commercial -X- _ O
vaccines -X- _ O
, -X- _ O
and -X- _ O
only -X- _ O
one -X- _ O
drug -X- _ O
with -X- _ O
significant -X- _ O
efficacy -X- _ O
against -X- _ O
adult -X- _ O
worms -X- _ O
and -X- _ O
juveniles. -X- _ O
A -X- _ O
liver -X- _ O
fluke -X- _ O
vaccine -X- _ O
is -X- _ O
deemed -X- _ O
essential -X- _ O
as -X- _ O
short-lived -X- _ O
chemotherapy -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
prone -X- _ O
to -X- _ O
resistance -X- _ O
, -X- _ O
is -X- _ O
an -X- _ O
unsustainable -X- _ O
option -X- _ O
in -X- _ O
both -X- _ O
developed -X- _ O
and -X- _ O
developing -X- _ O
countries. -X- _ O
Protein -X- _ O
superfamilies -X- _ O
have -X- _ O
provided -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
leading -X- _ O
liver -X- _ O
fluke -X- _ O
vaccine -X- _ O
candidates. -X- _ O
A -X- _ O
new -X- _ O
form -X- _ O
of -X- _ O
glutathione -X- _ O
transferase -X- _ O
( -X- _ O
GST -X- _ O
) -X- _ O
family -X- _ O
, -X- _ O
Sigma -X- _ B-Intervention
class -X- _ I-Intervention
GST -X- _ I-Intervention
, -X- _ O
closely -X- _ O
related -X- _ O
to -X- _ O
a -X- _ O
leading -X- _ O
Schistosome -X- _ O
vaccine -X- _ O
candidate -X- _ O
( -X- _ O
Sm28 -X- _ O
) -X- _ O
, -X- _ O
has -X- _ O
previously -X- _ O
been -X- _ O
revealed -X- _ O
by -X- _ O
proteomics -X- _ O
in -X- _ O
the -X- _ O
liver -X- _ B-Patient
fluke -X- _ I-Patient
but -X- _ O
not -X- _ O
functionally -X- _ O
characterised. -X- _ O
METHODOLOGY -X- _ O
/ -X- _ O
PRINCIPAL -X- _ O
FINDINGS -X- _ O
: -X- _ O
In -X- _ O
this -X- _ O
manuscript -X- _ O
we -X- _ O
show -X- _ O
that -X- _ O
a -X- _ O
purified -X- _ B-Intervention
recombinant -X- _ I-Intervention
form -X- _ I-Intervention
of -X- _ I-Intervention
the -X- _ I-Intervention
F. -X- _ I-Intervention
hepatica -X- _ I-Intervention
Sigma -X- _ I-Intervention
class -X- _ I-Intervention
GST -X- _ I-Intervention
possesses -X- _ O
prostaglandin -X- _ O
synthase -X- _ O
activity -X- _ O
and -X- _ O
influences -X- _ O
activity -X- _ O
of -X- _ O
host -X- _ O
immune -X- _ O
cells. -X- _ O
Immunocytochemistry -X- _ O
and -X- _ O
western -X- _ O
blotting -X- _ O
have -X- _ O
shown -X- _ O
the -X- _ O
protein -X- _ O
is -X- _ O
present -X- _ O
near -X- _ O
the -X- _ O
surface -X- _ O
of -X- _ O
the -X- _ O
fluke -X- _ O
and -X- _ O
expressed -X- _ O
in -X- _ O
eggs -X- _ O
and -X- _ O
newly -X- _ O
excysted -X- _ O
juveniles -X- _ O
, -X- _ O
and -X- _ O
present -X- _ O
in -X- _ O
the -X- _ O
excretory -X- _ O
/ -X- _ O
secretory -X- _ O
fraction -X- _ O
of -X- _ O
adults. -X- _ O
We -X- _ O
have -X- _ O
assessed -X- _ O
the -X- _ O
potential -X- _ O
to -X- _ O
use -X- _ O
F. -X- _ B-Intervention
hepatica -X- _ I-Intervention
Sigma -X- _ I-Intervention
class -X- _ I-Intervention
GST -X- _ I-Intervention
as -X- _ I-Intervention
a -X- _ I-Intervention
vaccine -X- _ I-Intervention
in -X- _ I-Intervention
a -X- _ I-Intervention
goat-based -X- _ I-Intervention
vaccine -X- _ I-Intervention
trial. -X- _ O
No -X- _ B-Outcome
significant -X- _ I-Outcome
reduction -X- _ I-Outcome
of -X- _ I-Outcome
worm -X- _ I-Outcome
burden -X- _ I-Outcome
was -X- _ I-Outcome
found -X- _ I-Outcome
but -X- _ I-Outcome
we -X- _ I-Outcome
show -X- _ I-Outcome
significant -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
pathology -X- _ I-Outcome
normally -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
liver -X- _ I-Outcome
fluke -X- _ I-Outcome
infection. -X- _ I-Outcome
CONCLUSIONS -X- _ O
/ -X- _ O
SIGNIFICANCE -X- _ O
: -X- _ O
We -X- _ O
have -X- _ O
shown -X- _ O
that -X- _ O
F. -X- _ B-Outcome
hepatica -X- _ I-Outcome
Sigma -X- _ I-Outcome
class -X- _ I-Outcome
GST -X- _ I-Outcome
has -X- _ I-Outcome
likely -X- _ I-Outcome
multi-functional -X- _ I-Outcome
roles -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
host-parasite -X- _ I-Outcome
interaction -X- _ I-Outcome
from -X- _ I-Outcome
general -X- _ I-Outcome
detoxification -X- _ I-Outcome
and -X- _ I-Outcome
bile -X- _ I-Outcome
acid -X- _ I-Outcome
sequestration -X- _ I-Outcome
to -X- _ I-Outcome
PGD -X- _ I-Outcome
synthase -X- _ I-Outcome
activity -X- _ I-Outcome
. -X- _ O

